- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06311227
Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia
A Phase 2 Study of Venetoclax in Relapsed Classic or Variant Hairy Cell Leukemia
Study Overview
Status
Detailed Description
PRIMARY OBJECTIVE:
I. To determine the objective response rate (ORR) of venetoclax.
SECONDARY OBJECTIVES:
I. To determine the complete remission (CR) and minimal residual disease (MRD)-negative CR rates of venetoclax in relapsed hairy cell leukemia/hairy cell leukemia variant (HCL/HCLv).
II. To determine the rates of MRD-negative by blood flow cytometry with venetoclax.
III. To determine the safety of venetoclax in relapsed HCL/HCLv. IV. To determine the response and CR duration and MRD-negative survival in relapsed HCL/HCLv receiving venetoclax.
EXPLORATORY OBJECTIVES:
I. To correlate response to TP53 mutations and other mutations, particularly for BRAF wild-type (WT) relapsed HCL/HCLv.
II. To perform whole exome sequencing (WES) of relapsed HCL/HCLv samples to look for mutations, to correlate with response.
OUTLINE:
Patients receive venetoclax orally (PO) once daily (QD) on days 1-28 of each cycle. Treatment repeats every 28 days for up to 19 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography (CT) or magnetic resonance imaging (MRI) and blood sample collection throughout the study. Patients may undergo bone marrow biopsy and/or aspiration on study.
After completion of study treatment, patients are followed up at 30 days.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients must have histologically or cytologically confirmed HCL/HCLv after purine analog therapy who are relapsed from or are ineligible for BRAF therapy and have not received prior venetoclax
- Age ≥ 18 years
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (Karnofsky ≥ 60%)
- Total bilirubin ≤ 3 x institutional upper limit of normal (ULN) unless consistent with Gilbert's (ration between total and direct bilirubin > 5)
- Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) ≤ 3 × institutional ULN
- Serum creatinine ≤ 2.0 mg/dL OR creatinine clearance ≥ 45 mL/min/1.73m^2
- Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
- For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
- Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
- Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
- Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
- Patients must have had no HCL/HCLv treatment for ≥ 4 weeks prior to enrollment, and those with treatment > 4 weeks prior to enrollment must not be responding to their last treatment with decreasing tumor burden or improving drug-related cytopenias
- Patients must have a need for treatment due to absolute neutrophil count (ANC) < 1/nL, hemoglobin (Hgb) < 10g/dL, platelets (Plt) < 100/nL, symptomatic splenomegaly, enlarging HCL mass > 2cm in short axis, enlarging HCL mass > 0.5 cm in the central nervous system (CNS) in short axis, or leukemic count > 5/nL
- The effects of venetoclax on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) during treatment and for 30 days after the last dose of venetoclax. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception during treatment and for 30 days after the last dose of venetoclax
- Ability to understand and the willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants
- Ability and willingness to swallow pills
Exclusion Criteria:
- Patients who have received prior venetoclax
- Patients who are receiving any other investigational agents
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to venetoclax
- Patients with uncontrolled intercurrent illness or any other significant condition(s) that would make participation in this protocol unreasonably hazardous
- Pregnant women are excluded from this study because venetoclax is a B-cell lymphoma-2 (BCL-2) inhibitor agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with venetoclax, breastfeeding should be discontinued if the mother is treated with venetoclax
- Malabsorption syndrome or other conditions that would interfere with intestinal absorption
- Live attenuated vaccines should not be administered within 4 weeks prior to, during, or 30 days after study treatment and recovery has occurred
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (venetoclax)
Patients receive venetoclax PO QD on days 1-28 of each cycle.
Treatment repeats every 28 days for up to 19 cycles in the absence of disease progression or unacceptable toxicity.
Patients undergo CT or MRI and blood sample collection throughout the study.
Patients may undergo bone marrow biopsy and/or aspiration on study.
|
Undergo MRI
Other Names:
Undergo blood sample collection
Other Names:
Given PO
Other Names:
Undergo CT scan
Other Names:
Undergo bone marrow aspiration
Undergo bone marrow biopsy
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate
Time Frame: Up to 30 days after the last dose
|
Will be determined with 95% confidence intervals for each group.
|
Up to 30 days after the last dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete remission (CR) rate
Time Frame: Up to 30 days after the last dose
|
CR will be defined as resolution of cytopenias with neutrophils > 1.5/nL, platelets > 100/nL, and hemoglobin > 11g/dL at least 4 weeks from last transfusion or growth factor, resolution of splenomegaly by exam or by spleen size < 17 cm by imaging, resolution of hairy cell leukemia (HCL)/hairy cell leukemia variant (HCLv)-related lymphadenopathy/masses to < 2cm in short axis (< 0.5 cm in short axis in the central nervous system [CNS]), and absence of morphological evidence of HCL/HCLv in the blood and bone marrow.
|
Up to 30 days after the last dose
|
Minimal residual disease (MRD)-negative CR rate
Time Frame: Up to 30 days after the last dose
|
Defined as meeting the criteria for CR plus absence of HCL/HCLv cells in the bone marrow aspirate and blood by flow cytometry, and negative immunochemistry of the bone marrow biopsy.
Positive IHC involves B-cells > T-cells and most of the B-cells being consistent with HCL.
Patients with CNS disease who achieve CR with positive cerebrospinal fluid flow cytometry will be considered CR with MRD.
|
Up to 30 days after the last dose
|
MRD negativilty
Time Frame: Up to 30 days after the last dose
|
Will determine the rates of MRD-negative by blood flow cytometry.
|
Up to 30 days after the last dose
|
Incidence of adverse events
Time Frame: Up to 30 days after the last dose
|
Up to 30 days after the last dose
|
|
Complete response duration
Time Frame: Up to 30 days after the last dose
|
Up to 30 days after the last dose
|
|
MRD-negative survival
Time Frame: Up to 30 days after the last dose
|
Up to 30 days after the last dose
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
TP53 mutations and other mutations
Time Frame: Up to 30 days after the last dose
|
Will correlate response to TP53 mutations and other mutations.
|
Up to 30 days after the last dose
|
Whole exome sequencing of relapsed HCL/HCLv samples
Time Frame: Up to 30 days after the last dose
|
Will perform whole exome sequencing of relapsed HCL/HCLv samples to look for mutations, to correlate with response.
|
Up to 30 days after the last dose
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Robert J Kreitman, National Cancer Institute LAO
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NCI-2024-01904 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- 10637 (Other Identifier: CTEP)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Hairy Cell Leukemia
-
National Cancer Institute (NCI)Active, not recruitingHairy Cell Leukemia | Recurrent Hairy Cell Leukemia | Hairy Cell Leukemia VariantUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingHairy Cell Leukemia | Recurrent Hairy Cell LeukemiaUnited States
-
National Cancer Institute (NCI)RecruitingHairy Cell Leukemia | Hairy Cell Leukemia VariantUnited States
-
Memorial Sloan Kettering Cancer CenterYale University; Dana-Farber Cancer InstituteActive, not recruitingLeukemia | Leukemia, Hairy Cell | Hairy Cell LeukemiaUnited States
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI); Northwestern University; Northwell Health; Dana-Farber... and other collaboratorsActive, not recruitingHairy Cell LeukemiaUnited States
-
MedImmune LLCCambridge Antibody TechnologyCompletedHairy Cell LeukemiaUnited States, Poland
-
National Cancer Institute (NCI)TerminatedHairy Cell LeukemiaUnited States
-
Jurgen BarthCompletedHairy Cell Leukemia (HCL)Germany
-
AstraZenecaApproved for marketingRelapsed/Refractory Hairy Cell Leukemia
-
Power Life Sciences Inc.Not yet recruitingHairy Cell Leukemia
Clinical Trials on Magnetic Resonance Imaging
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Recruiting
-
M.D. Anderson Cancer CenterActive, not recruitingProstate Adenocarcinoma | Prostate CarcinomaUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityRecruitingIntracranial NeoplasmUnited States
-
University of California, San FranciscoTerminatedAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Healthy SubjectUnited States
-
Stanford UniversityTerminatedLaryngeal Neoplasms | Head and Neck Cancers | Larynx CancerUnited States
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)CompletedBreast CancerUnited States
-
Abramson Cancer Center of the University of PennsylvaniaCompletedBrain TumorUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedThoracic Spine NeoplasmUnited States